RefleXion PET/CT Imaging Performance in Patients With Various Malignancies
Launched by CITY OF HOPE MEDICAL CENTER · May 3, 2023
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging system called the RefleXion Medical Radiotherapy System (RMRS) to see how well it works compared to the standard imaging method known as PET-CT scans in patients with different types of cancer. PET-CT scans use a small amount of a radioactive substance to highlight cancer cells, allowing doctors to see where the cancer is in the body. The goal of this trial is to determine if the RMRS can improve the quality of imaging and help plan radiation therapy more efficiently, potentially reducing the number of scans needed.
To participate in this trial, patients must be at least 21 years old and have been diagnosed with various cancers, such as tumors in the abdomen, pelvis, chest, head, neck, or breast. They should already be scheduled for a standard PET-CT scan before joining the study. It's important to note that individuals with certain psychiatric or substance abuse issues, those who weigh more than 450 pounds, and patients with specific tumor types will not be eligible for this trial. Participants can expect to undergo imaging using the new system and contribute to research that could enhance cancer treatment in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented informed consent of the participant and/or legally authorized representative
- • Age: \>= 21 years
- • Patients with malignancies (abdominal/pelvic/thoracic/head and neck/breast tumors) undergoing SOC \[18F\]-FDG PET-CT for diagnostic and/or radiotherapy planning purposes
- • Patients should be scheduled for \[18F\]-FDG PET-CT prior to study entry
- Exclusion Criteria:
- • Known psychiatric or substance abuse disorder that would interfere with conduct of the study
- • Patient weight exceeding the weight limit (450 pounds) outlined per X1 RMRS specifications sheet
- • Lung parenchymal and bone tumors will be excluded as their imaging characteristics were evaluated in a previous study
About City Of Hope Medical Center
City of Hope Medical Center is a leading research and treatment institution located in Duarte, California, dedicated to advancing innovative therapies and improving patient outcomes in the fields of cancer, diabetes, and other life-threatening diseases. With a strong emphasis on translational medicine, City of Hope combines cutting-edge research with compassionate care, fostering a collaborative environment for clinical trials that aim to bring new treatments from the laboratory to the bedside. The center is recognized for its commitment to patient-centered care and its role as a National Cancer Institute-designated Comprehensive Cancer Center, making it a pivotal player in the landscape of medical research and clinical innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Duarte, California, United States
Patients applied
Trial Officials
Jeffrey Y Wong
Principal Investigator
City of Hope Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported